- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07765173
Muscle Function Following Anterior Cruciate Ligament Reconstruction: Impaired Power Output in Physically Active Individuals (ReGAIN)
The goal of this clinical trial is to to determine the extent of the association between objective changes in the muscle function of the knee extensors (strength and power) and the function reported by the patient following ACL reconstruction surgery. The main questions it aims to answer is:
- Pre- and post-operative (6 months) changes in maximum knee extensor strength following ACL reconstruction, correlated with the IKDC-SKF score.
Study Overview
Detailed Description
Before surgery :
- The patient will undergo a series of assessment tests, including:
- An assessment of the force-velocity and power-velocity relationships for each leg during a cycling task
- An assessment of unilateral force-velocity and power-velocity relationships during a knee extension task
- An assessment of maximum strength and explosive strength in isometric (static) mode of the knee extensors.
- A questionnaire-based assessment of IKDC-SKF scores. Evaluations will be repeated at 3 and 6 month after surgery ; Patients will be monitored for up to 24 months following their surgery
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: leo blervaque
- Phone Number: 04.79.96.58.13
- Email: leo.blervaque@ch-metropole-savoie.fr
Study Locations
-
-
-
Challes-les-Eaux, France, 73190
- Recruiting
- Médipôle de Savoie
-
Contact:
- Vincent Morin
- Phone Number: 04 79 26 80 80
- Email: urc@ch-metropole-savoie.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients requiring isolated or complex ACL reconstruction (combined with a meniscal injury)
- Patients who are physically active (Tegner score ≥ 4) and wish to resume such activity.
- Patients with no history of surgery on the ipsilateral knee (i.e., native knee).
- Patients able to comply with the study procedures
- Patients who have given their free and informed written consent, having been informed of the purpose of the study, its procedure and its risks.
- Be affiliated to a social security scheme.
Exclusion Criteria:
- Patient with comprehension difficulties
- Recurrent rupture of the ipsilateral ACL
- Multi-ligament injuries (i.e., injury to the medial collateral ligament, lateral collateral ligament or posterior cruciate ligament)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: evaluated group
assessment of knee function before and after cruciate ligament surgery
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of maximum knee extension strength to IKDC-SKF scores
Time Frame: 6 month
|
Relationship (r coefficient) between 0-6 month delta of maximum knee extension strength measurements and International Knee Documentation Commitee-SKF scores (100: no limitation)
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peri-operatory trajectory of maximal dynamic force
Time Frame: 0, 3 and 6 month
|
Trajectory of evolution of F0 (maximal dynamic force) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
|
0, 3 and 6 month
|
|
Peri-operatory trajectory of maximal contraction velocity
Time Frame: 0, 3 and 6 month
|
Trajectory of evolution of V0 (maximal contraction velocity) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
|
0, 3 and 6 month
|
|
Peri-operatory trajectory of rate of force development
Time Frame: 0, 3 and 6 month
|
Trajectory of evolution of rate of force development between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
|
0, 3 and 6 month
|
|
Peri-operatory trajectory of maximal isometric force
Time Frame: 0, 3 and 6 month
|
Trajectory of evolution of maximal isometric force (Fmax) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
|
0, 3 and 6 month
|
|
Peri-operatory trajectory of maximal dynamic force during cycling
Time Frame: 0, 3 and 6 month
|
Trajectory of evolution of maximal dynamic force (F0) during cycling between baseline, 3 and 6 months (linear mixed effect model, one fixed factor).
|
0, 3 and 6 month
|
|
Peri-operatory trajectory of maximal contraction velocity during cycling
Time Frame: 0, 3 and 6 month
|
Trajectory of evolution of maximal contraction velocity (V0) during cycling between baseline, 3 and 6 months (linear mixed effect model, one fixed factor).
|
0, 3 and 6 month
|
|
Determinants of fonctional prognosis
Time Frame: 0, 3 and 24 month
|
Multivariate analysis including the IKDC-SKF score at 24 months as dependant variable and, as predictors :
|
0, 3 and 24 month
|
|
Determinants of fonctional prognosis
Time Frame: 0, 3 and 24 month
|
Multivariate analysis including the recurrence of ACL lesion at 24 months (0/1) as dependant variable and, as predictors :
|
0, 3 and 24 month
|
|
Determinants of fonctional prognosis
Time Frame: 0, 3 and 24 month
|
Multivariate analysis including resuming physical activity at the pre-injury level at 24 months (0/1) as dependant variable and, as predictors :
|
0, 3 and 24 month
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHMS26001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.